How many FDA warning letters has Sato Pharmaceutical Co., Ltd. received?

Argus HQ has recorded 1 FDA warning letter for Sato Pharmaceutical Co., Ltd..

What FDA recalls has Sato Pharmaceutical Co., Ltd. issued?

Argus HQ has not recorded an FDA recall tied to Sato Pharmaceutical Co., Ltd. in our current dataset.

Is Sato Pharmaceutical Co., Ltd. FDA compliant?

Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 1 warning letter, 0 recalls, and 0 approval records for Sato Pharmaceutical Co., Ltd.. Review the linked FDA source records directly before drawing a compliance conclusion.

.hq

company

Sato Pharmaceutical Co., Ltd.

Name: FDA Enforcement Actions Against Sato Pharmaceutical Co., Ltd.
Creator: Argus HQ
License: https://argushq.ai/methodology

Industry: pharmaceutical

Jurisdiction: US

FDA Warning Letter timeline

V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.

fda_warning_letter · cgmp2026-05-18
Sato Pharmaceutical Co., Ltd. — CGMP/Drugs/Adulterated/OTC (2026-05-18)
fda_483 · inspection_citation2025-11-21
Sato Pharmaceutical Co., Ltd. -- FDA 483: 1 observation (2025-11-21)

Frequently asked questions

How many FDA warning letters has Sato Pharmaceutical Co., Ltd. received?: Argus HQ has recorded 1 FDA warning letter for Sato Pharmaceutical Co., Ltd..
What FDA recalls has Sato Pharmaceutical Co., Ltd. issued?: Argus HQ has not recorded an FDA recall tied to Sato Pharmaceutical Co., Ltd. in our current dataset.
Is Sato Pharmaceutical Co., Ltd. FDA compliant?: Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 1 warning letter, 0 recalls, and 0 approval records for Sato Pharmaceutical Co., Ltd.. Review the linked FDA source records directly before drawing a compliance conclusion.

Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.